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Abstract: Anticoagulation is indicated in most cardioembolic ischemic strokes for secondary prevention. In many cardiac 
conditions, anticoagulation is also indication for primary stroke prevention, mainly when associated to vascular risk 
factors. Anticoagulation should be started as soon as possible, as it is safe even in moderate acute strokes. The efficacy of 
early anticoagulation after cardioembolic stroke in relation to outcome has not been assessed adequately, but there is 
evidence from animal models and clinical studies that anticoagulation with unfractionated heparin is associated with a 
better outcome mediated in part by its anti-inflammatory properties. 
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ANTICOAGULATION IN CARDIOEMBOLIC 
STROKE PREVENTION 
  Oral anticoagulation (OAC) is the treatment of choice for 
secondary prevention after a cardioembolic stroke [1, 2]. 
Warfarin is the commonest OAC used worldwide, although 
acenocumarol, phenprocoumon or anisidione are frequently 
prescribed in many countries. The mechanisms of action of 
these OAC are comparable, as they inhibit the vitamin K-
dependent post-translational carboxylation of glutamate 
residues on the N-terminal regions of coagulation factors II, 
VII, IX, and X by inhibiting the conversion of vitamin 2,3 
epoxide to reduced vitamin K [3]. Although the benefits of 
OAC are supported by a high degree of evidence for stroke 
prevention in cardioembolic entities, such as atrial fibril-
lation [4], they have a narrow therapeutic index, numerous 
drug and dietary interactions, and a significant risk of serious 
bleeding, including hemorrhagic stroke [5].  
Atrial Fibrillation  
  Atrial fibrillation (AF) is the most frequent cardiac 
condition associated to the risk of ischemic stroke, although 
it is only weakly associated with transient ischemic attack 
(TIA) [6]. The incidence of ischemic stroke among patients 
with AF not treated with antithrombotic agents averages 
4.5% per year, and it may be as high as 13% per year in 
certain high-risk groups. Overall, AF increases the risk of 
stroke fourfold to fivefold across all age groups [7]. Patient-
level meta-analyses of the efficacy of antithrombotic 
therapies in AF from pooled data of randomized trials 
showed that adjusted-dose oral anticoagulation (target 
International Normalized Ratio (INR) 2.5; range, 2.0-3.0) 
resulted in a relative risk reduction of 68% (95%CI 50%-
70%) compared to no antithrombotic therapy [7]. Oral 
anticoagulation (INR 2.0–3.0) reduces the risk of recurrent 
stroke in patients with non-valvular AF, regardless of the 
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type (permanent, chronic or paroxysmal) [8]. Aspirin 
resulted in a relative risk reduction of 21% (95%CI 0%-38%) 
compared to no antithrombotic therapy [9], and adjusted-
dose oral anticoagulation resulted in a relative risk reduction 
of 52% (95%CI 37%-63%) compared to aspirin, respectively 
[10].  
  In primary prevention studies OAC lowered the mortality 
rate by 33% (95%CI 9%-51%), and the combined outcome 
of stroke, systemic embolism, and death by 48% (95%CI 
34%-60%) [11]. In these studies, the reported annual 
incidence of major bleeding and intracranial hemorrhage was 
1.3% and 0.3% in anticoagulated patients, compared to 1% 
and 0.1% in control patients. The risk of intracranial hemorr-
hage is significantly increased at INR values >4.0, with 
increasing age, and in patients with a history of stroke [12]. 
  From the available information it is clear that oral 
anticoagulation is more efficacious and more risky than 
aspirin to prevent first stroke in patients with AF [2]. Despite 
the encouraging results of OAC in AF, this treatment is 
underutilized in clinical practice as more than one third of 
eligible patients in primary care practice are not receiving it 
[13], and subtherapeutic INR are encountered in 45% of 
patients taking OAC [14]. 
  Several risk stratification schemes have been developed 
in order to maximize the benefits of the antithrombotic 
treatment to prevent the risk of first stroke in individual 
patients (Table 1). Primary prevention patients whose stroke 
risk exceeds 4 per 100 patient-years on aspirin benefit from 
oral anticoagulation [11]. Stroke prone patients are reliably 
identified by a CHADS(2) score > 3, and they have an 
average risk of 5.5 strokes per 100 patient-years on aspirin 
[15]. High risk primary prevention patients are less well 
identified with the other schemes described in the table. Yet, 
all schemes are equally sensitive to detect low-risk patients 
whose stroke rate is 1.4 or lower per 100 patient-years of 
aspirin. Oral anticoagulation is more effective in patients 
with AF who have one or more risk factors, such as previous 
systemic embolism, age over 75 years, high blood pressure 
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  There has been some concern about the risk/benefit of 
oral anticoagulation in elderly patients, because of a greater 
risk of hemorrhagic complications in this group of patients. 
However, the WASPO (Warfarin vs. Aspirin for Stroke 
Prevention in Octogenarians) [17] and BAFTA (Birmingham 
Atrial Fibrillation Treatment of the Aged) [18] trials have 
shown that OAC is safe and effective in older individuals. 
Therefore, there is no justification to avoid anticoagulation in 
very old individuals with AF, unless there is a clear contrain-
dication.  
  Other approach that has been tested in the prevention of 
vascular events in patients with AF is the combination of 
aspirin and clopidogrel. The ACTIVE W (Atrial fibrillation 
Clopidogrel Trial with Irbesartan for prevention of Vascular 
Events) study found that the combination of aspirin and 
clopidogrel was less effective than warfarin and had a similar 
bleeding rate [19]. In the ACTIVE A trial, 7554 patients with 
AF who were considered unsuitable to receive vitamin-K 
antagonist therapy were randomized to received clopidogrel 
(75 mg/day) or placebo added to aspirin [20]. The addition of 
clopidogrel to aspirin reduced the rate of major vascular 
events from 7.6% per year to 6.8%, primarily due to a 
reduction in the rate of stroke [20]. However, the rate of 
major hemorrhage increased from 1.3% to 2.0% per year. 
The trial suggests that there is an important role of abnormal 
platelet activation in the pathogenesis of stroke in atrial 
fibrillation, and that antiplatelet combination therapy could 
be beneficial in patients considered to be at risk if treated 
with vitamin-K antagonist. One disabling of fatal stroke 
would be prevented for every approximately 200 patients 
treated for 1 year [21]. However, the composite of the 
primary outcome and major hemorrhages between groups 
was similar, with 968 events in the clopidogrel and aspirin 
group versus 966 events in the aspirin-only group [22]. One 
of the main problems of the study is that there was not a 
clear definition of which groups of patients are unsuitable to 
receive oral anticoagulation therapy. In the light of the 
results of these trials, OAC should be the preferred and 
recommended therapy for the prevention of stroke in patients 
with AF at a high risk for vascular events [23]. Moreover, 
only 23% of the patients recruited in the trial had a verified 
cause of increased bleeding risk that made them really 
unsuitable for OAC therapy. A major lesson of this 
observation is the urgent need to implement in future clinical 
trials more refined ways to identify patient and clinical 
preferences for health states and treatments once AF is 
identified [23]. Underutilization of OAC therapy in AF is 
more consistent with physician rather than patient values 
[24]. 
  It has been argued that an individualized stroke pre-
diction, particularly in low risk patients, could improve the 
risk benefit of anticoagulation in AF. In some studies [25, 
26] prothrombin activation fragment 1.2 (F1.2) and 
thrombin-antithrombin III complexes (TAT), markers of 
thrombin generation, fibrinopeptide A (FPA), reflecting 
thrombin activity, D-dimer, a breakdown product of fibrin, 
and  -thromboglobulin and platelet factor 4, were found 
elevated in plasma in patients with AF. Levels may be higher 
in patients with spontaneous echo contrast [27]. Higher 
hematocrit, plasma viscosity, erythrocyte sedimentation rate, 
fibrinogen, and membrane-bound and soluble P-selectin, 
were also found independently associated with spontaneous 
echo contrast in patients with AF [28]. Persistently elevated 
levels of D-dimer and tissue plasminogen activator antigen 
during oral anticoagulant therapy have been identified in 
individuals at risk for cardiovascular events [29]. C-reactive 
protein was found increased in patients with AF compared 
with controls [30], and it was recently been suggested as an 
independent predictor of future development of AF [31]. 
Nonetheless, biomarkers are not widely used in clinical 
practice to identify stroke prone AF. 
  There are other alternatives to OAC that have been 
explored for stroke prevention in AF patients, such as 
indobufen, a reversible inhibitor of platelet cyclooxygenase 
activity. The SIFA trial was a prospective, randomized, open 
study involving a total of 916 patients with non-valvular AF 
and a recent cerebral ischemic episode. Patients received 
either indobufen (100 or 200 mg BID) or warfarin (INR 2.0 
to 3.5) for 12 months. The combined incidence of nonfatal 
stroke (including intracerebral bleeding), pulmonary or 
systemic embolism, nonfatal myocardial infarction, and 
vascular death was not significantly different between the 
two treatment groups [32]. However, the limited power of 
the study did not exclude the existence of substantial 
differences between the two treatments.  
Table  1.  Stroke Risk Stratifications Schemes in Patients with Non-Valvular Atrial Fibrillation. (BP: Blood Pressure, DM: 
Diabetes Mellitus, CHF: Congestive Heart Failure, TIA: Transient Ischemic Attack, CAD: Coronary Artery Disease, 
LV: Left Ventricular Fractional Shortening)  
Scheme  Low Risk  Moderate Risk  High Risk 
AFI [7]  Not moderate/high risk  Age>65, not high risk  Prior ischemia, High BP, DM 
SPAF [116]  Not moderate/high risk  High BP, not high risk 
Prior ischemia, female>75 yrs, CHF, LV < 25%, 
systolic BP > 160 
ACCP [11, 117]  Not moderate/high risk 
1 of: 65-75 yrs, DM, CAD and not 
high risk 
Prior ischemia, high BP, CHF, >75 yrs, or  2 
moderate risk factors 
CHADS2 [15]  SCORE=+1 for CHF, high BP, DM, >75yr, and +2 for prior stroke/TIA 
FRAMINGHAM [118]  SCORE=+6 for prior ischemia, 0 to 4 for BP, +4 for DM, + 0 to 10 for age, 6 for female Antithrombotic Therapy in Cardiac Embolism  Current Cardiology Reviews, 2010, Vol. 6, No. 3    229 
  Ximelagatran is an oral direct thrombin inhibitor that 
inhibits the conversion of fibrinogen to insoluble fibrin by 
thrombin which has also been explored in patients with AF. 
The drug binds only to the active site of thrombin and does it 
reversibly, inhibiting not only free thrombin but also clot-
bound thrombin. In the SPORTIF III trial [33], patients with 
AF were randomized to treatment with a fixed dose of 
ximelagatran (36 mg twice daily) or warfarin dose-adjusted 
(target INR 2.0 to 3.0). Primary events occurred in 2.3% of 
patients taking warfarin and in 1.6% in the ximelagatran 
group (p=0.1). The rates of combined minor and major 
hemorrhages were lower with ximelagatran (29.8% vs. 25%; 
relative risk reduction 14%; p=0.007) [33]. The risk of 
intracranial hemorrhage was 0.19% per year for warfarin and 
0.11% per year in ximelagatran, and the annual rates of 
ischemic strokes were 1.46% and 1.37%, respectively. Major 
bleeding occurred at an annual rate of 2.5% in the warfarin-
treated group, and 1.9% in the ximelagatran-treated group, a 
non significant difference. The majority of ischemic strokes 
were non cardioembolic in origin, typically lacunar or large-
artery atherosclerosis-related strokes. However, in 6.1% of 
patients receiving ximelagatran there was an increase in 
alanine aminotransferase greater than 3 times the upper limit 
of normal. In the SPORTIF V trial [34], (a double-blind trial 
involving relatively high-risk patients with non valvular AF), 
ximelagatran was not inferior to well-controlled warfarin 
within the prespecified margin of 2.0% per year for 
prevention of stroke and systemic embolism. However, 3 
deaths with liver failure were reported in the trials, and it 
was estimated 1 death from hepatic failure among 2300 
patients treated [35]. In data presented to the Food and Drug 
Administration (FDA) on all patients receiving long-term 
ximelagatran, an increase in alanine aminotransferase >3 x 
normal occurred in 7.9% of patients compared with 1.2% of 
patients receiving comparator therapy, leading the FDA to 
deny approval of ximelagatran because of concerns about 
hepatotoxicity [36]. Later on the sponsor officially notified 
the Committee for Medicinal products for Human Use that it 
whished to withdraw its application for a marketing 
authorization for ximelagatran for the prevention of stroke 
associated with AF.  
  Dabigatran is a potent, direct, competitive inhibitor of 
thrombin that, like ximelagatran, does not require regular 
monitoring [37]. In the RE-LY trial (Randomized Evaluation 
of Long-Term Anticoagulation Therapy) two fixed doses of 
dabigatran (110 mg or 150 mg, twice daily) administered in a 
blinded manner were compared to open-label use of warfarin 
in 18,113 patients with AF [38]. The primary outcome 
measure was stroke or systemic embolism, and the primary 
safety outcome was major hemorrhage. Stroke or systemic 
embolism occurred in 1.53% per year in patients receiving 
110 mg of dabigatran, 1.11% per year with 150 mg dabiga-
tran, and 1.69% per year in patients receiving warfarin, with 
a median duration of follow-up of 2.0 years [38]. Both doses 
were non-inferior to warfarin, and the 150 mg dose was 
shown to be superior to warfarin (RR 0.66, 95%CI 0.53 to 
0.82). Hemorrhagic stroke happened in 0.38% per year with 
warfarin, 0.12% per year with 110 mg dabigatran, and 0.10% 
per year with 150 mg dabigatran. Only major gastrointestinal 
bleeding was more frequent in patients taking 150 mg 
dabigatran in comparison to warfarin. In this study, there 
were no significant increases in liver enzymes with 
dabigatran [38]. The only adverse event that was more 
frequent with dabigatran was dyspepsia. The conclusion of 
this trial was that both doses of dabigatran were non inferior 
to warfarin in the prevention of stroke or systemic embolism. 
Moreover, the dose of 150 mg was superior to warfarin for 
embolic prevention, and the dose of 110 mg produced less 
hemorrhagic events. Therefore, the authors suggested that 
the dose of dabigatran could potentially be tailored to take 
into consideration the risk characteristics of a specific patient 
[38]. Nevertheless, it has to be taken in consideration that the 
number of patients needed to be treated with dabigatran at a 
dose of 150 mg to prevent one non hemorrhagic stroke, in 
comparison to warfarin, is approximately 357 [39]. For this 
reason and due to a greater risk of non hemorrhagic side 
effects and a twice-daily dosing, some authors think that 
switching to dabigatran would not be of great value in 
patients on warfarin with a good INR control [39].  
Pacemakers  
  Pacemakers are needed to treat many cardiac conditions, 
but its presence may obscure the diagnosis of important 
concomitants factors such as AF. Indeed, many patients with 
pacemakers develop AF, and some patients with AF have 
concomitant sinus node dysfunction, thus requiring the use 
of pacemakers [40]. The lack of diagnose of AF may lead to 
the omission of appropriate treatment with OAC. Thus, 
patients with AF after pacemaker implantation may have a 
70% higher relative risk of stroke than patients without AF, 
even after adjustment for important clinical predictors [41]. 
Patients on pacemakers for sinus node dysfunction had an 
actuarial incidence of stroke of 3% at one year, and 5% at 
five years, and 13% at 10 years [42]. Pacemakers have 
different modes of programming and stimulation, and the 
incidence of AF and embolism may differ accordingly. The 
MOST study compared ventricular rate-modulated pacing 
with dual-chamber rate-modulated pacing in 2,010 patients 
followed for five years and whose sinus node dysfunction 
required permanent pacing for bradycardia [43]. The 
incidence of stroke in the first year after implant was only 
2.2% (95% CI 1.6 to 2.9), most likely because of the high 
use of antithrombotic agents, particularly in patients with AF 
[43]. Prior stroke, TIA, systemic embolism, age, hyperten-
sion, and NYHA functional class before pacemaker implan-
tation, but not mode of pacing, were associated with the risk 
of stroke [43]. In other studies mortality and incidence of 
stroke were not reduced by physiologic pacing, although this 
treatment modality was associated with a significant relative 
risk reduction in the incidence of AF (18% at 3 years and 
20% at 6 years) [44].  
Acute Myocardial Infarction  
  Stroke is a rare but feared complication of acute 
myocardial infarction (AMI) [45]. The long-term risk of 
stroke following AMI it is estimated in 1 to 2 % per year. A 
case-control study showed that stroke secondary to AMI 
causes a severer neurological deficit, more unfavorable 
clinical course, and higher mortality than stroke in patients 
without a recent AMI [46]. The risk of recurrent myocardial 
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OAC compared to aspirin therapy in one study that allocated 
the antithrombotic regimens within 8 weeks of AMI or 
unstable angina [47]. Aspirin with medium-intensity OAC 
was also more effective than aspirin on its own in reduction 
of subsequent cardiovascular events and death. Therefore, it 
is recommended that OAC should be taken long term, or for 
at least 3 months after cardioembolic stroke due to AMI [48]. 
Congestive Heart Failure  
  The incidence of thromboembolism secondary to 
congestive heart failure (CHF) varies depending on the 
prospective or retrospective design of the studies, and 
whether clinical or autopsy data are assessed. Prospective 
studies of patients with dilated cardiomyopathy have 
reported a stroke incidence of 1.7 per 100 patient-years [49], 
while retrospective studies have given an incidence of 3.5 
symptomatic events per 100 patient-years [50]. A controlled 
trial of OAC among patients with CHF has not been 
performed, although certain groups of patients with CHF 
have well defined indications for chronic anticoagulation, 
such as previous thromboembolic event, AF, or the presence 
of newly formed left ventricular thrombus [51, 52]. Evidence 
from published reports does not demonstrate convincingly 
that the benefits of OAC exceed the risks. The SAVE [53] 
and SOLVD [54] databases have shown that low dose aspirin 
may be useful in preventing thromboembolism and may be 
less risky than OAC. In patients with underlying coronary 
artery disease, aspirin probably confers additional benefit. In 
the SAVE trial [53], aspirin use significantly reduced the risk 
of stroke by 56%, and the protective effect of aspirin was 
most pronounced in patients with a left ventricular ejection 
fraction < 28%; in this group, aspirin use was associated 
with a reduction in risk of stroke of 66% (p < 0.001). 
Similarly, the SOLVD trial [54] showed a beneficial effect 
of aspirin, especially in women. The use of antiplatelet 
agents was associated with a 23% reduction in the risk of 
embolism in men and 53% reduction in women. Aspirin was 
also associated with a 24% reduction in the risk of sudden 
death [54]. The V-HeFT studies failed to show any protec-
tive effect of anticoagulation [55]. Indeed, V-HeFT II 
showed that patients receiving anticoagulation had a higher 
thromboembolic event rate (4.9 per 100 patient-years) than 
those not receiving anticoagulation (2.1 per 100 patient-
years). Because neither the decision to initiate anticoagu-
lation nor the intensity of anticoagulation was controlled, it 
is likely that patients judged to be at highest embolic risk 
(e.g., those with AF or known LV thrombus or even patients 
with mechanical valve replacement) were treated with OAC.  
Cardiac Procedures  
  The reported incidence of symptomatic stroke after 
coronary artery bypass grafting (CABG) is between 0.8% 
and 5.2% [56]. Coronary bypass surgery without cardiopul-
monary bypass (off-pump CABG) is theoretically associated 
with a lower risk of stroke, given its advantages of no aortic 
manipulation, no hypothermia, and no use of the cardiopul-
monary bypass pump [57]. In a large study with 16,184 
patients the incidence of stroke was lower in the off-pump 
group (2.5%) compared to the conventional CABG group 
(3.9%) [58]. Embolism has been implicated in the 
pathophysiology of stroke after on-pump CABG, whereas 
myocardial stunning and hypoperfusion may be possible 
mechanisms associated with delayed onset of stroke after 
off-pump CABG [57]. However, postoperative Diffusion-
Weighted Imaging have shown similar rate of ischemic 
lesions in off-pump as opposed to on-pump CABG [59], 
suggesting that factors other than the use of the cardiopul-
monary bypass are associated with postoperative ischemic 
lesions. The timely administration of platelet inhibitors 
and/or per-operative anticoagulation, as well as prevention of 
hypotensive episodes may be indicated in off-pump CABG 
as preventive measures against delayed onset of stroke. Yet, 
further studies are needed to prospectively investigate the 
potential benefits of pharmaceutical agents in reducing the 
incidence of stroke after CABG. Acute stroke after 
percutaneous coronary intervention (PCI), although rare, is 
associated with high rates of mortality and morbidity [60]. 
The incidence of stroke and TIA ranges from 0.27% to 
0.50% [60, 61]. Appropriate use of antiplatelet agents and 
anticoagulants during PCI is aimed at improving early 
clinical outcome, and preventing local complications at the 
site of intervention which might increase the risk of stroke 
[62].  
Patent Foramen Ovale (PFO)  
  Patent foramen ovale (PFO) has been identified as a 
potential cause of stroke, although the association may be 
age-dependent [63]. Because stroke occurs more frequently 
in older population, with only 3% of cerebral infarctions 
occurring in patients younger than 40 years, the number of 
stroke patients with PFO older than 40 years is much larger 
than in younger patients [63]. The association of PFO with 
cryptogenic stroke in older patient populations is conflicting 
[64]. In the Stroke Prevention: Assessment of Risk in a 
Community (SPARC) echocardiography study [65], PFO 
was not a significant independent predictor of stroke (HR 
1.46, 95%CI 0.74 to 2.88). The secondary stroke prevention 
in patients with PFO has been evaluated in several studies. In 
the PFOASA study young patients (from 18 to 55 years) 
with cryptogenic stroke within the preceding 3 months were 
prospectively followed during 4 years of aspirin therapy (300 
mg per day)[66]. The risk of recurrent stroke was 2.3% in 
patients with PFO alone, 15.2% among patients with both 
PFO and atrial septal aneurysm (ASA), 4.2% among patients 
with neither of these cardiac abnormalities, and 0% in 
patients with ASA alone. The PICSS trial evaluated older 
stroke patients (from 30 to 85) with or without PFO who 
were randomized to receive aspirin (325 mg) or warfarin 
(INR 1.7 to 2.2) [67]. Regardless of treatment, the rate of 
recurrent stroke or death in patients with PFO (9.5%) was 
not significantly different than in patients without PFO 
(8.3%). Moreover, larger PFO were associated with a lower, 
not higher, overall rate of recurrent stroke or death (18.5% 
with small PFO versus 9.5% with large PFO), and the 
coexistence of PFO and ASA did not increase stroke risk 
[67]. Currently, the evidence is insufficient to determine if 
OAC is superior to aspirin for the prevention of recurrent 
stroke or death in patients with cryptogenic stroke and PFO, 
or the value of surgical or endovascular closure. The Rando-
mized Evaluation of Recurrent Stroke Comparing PFO 
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(RESPECT) trial, the CLOSURE I trial, and the CardiaPFO 
trial are currently comparing medical and percutaneous 
closure approaches, but large patient enrolment would be 
necessary due to the low event rate in these patients.  
Rheumatic Mitral Valve Disease  
  Recurrent embolism occurs in 30 to 65% of patients with 
rheumatic mitral valve disease, 60 to 65% during the first 
year, and most within 6 months. Although never evaluated 
by randomized clinical trials, there is little doubt that long-
term OAC therapy (target INR 2.0-3.0) is effective in 
reducing the incidence of systemic emboli in these patients 
[2]. Patients with rheumatic valve disease and AF or with 
previous systemic embolism should be offered treatment 
with long-term OAC. Exceptions include pregnant women or 
the patient at high risk for serious bleeding [68]. In patients 
with recurrent embolism despite being treated with OAC at a 
therapeutic INR, is recommended to add aspirin (75-100 
mg/d), dipyridamole (400 mg/d), or clopidogrel (75 mg/d) 
[68].  
Mechanical Prosthetic Heart Valves  
  It is well established that patients with all types of 
mechanical valves require antithrombotic prophylaxis for 
stroke prevention [68]. Lack of prophylaxis in patients with 
St. Jude Medical bileaflet valves is associated to embolism 
or valve thrombosis in 12% per year with aortic valves, and 
22% per year with mitral valves [69]. For patients with St. 
Jude Medical bileaflet and Medtronic Hall tilting disk 
mechanical valves in the aortic position, with no AF or 
enlarged left atrium, a target INR 2.0 - 3.0 is satisfactory 
[70]. An INR target 2.5-3.5 is satisfactory for tilting disk 
valves and bileaflet prosthetic valves in the mitral position 
[71]. In older devices, such as caged ball or caged disk valve, 
the optimal INR for thromboembolic prevention has be to 
higher, from 4.0 to 4.9 [71]. The combination of OAC and 
aspirin may be particularly useful in patients with prosthetic 
valves who have coronary artery disease or stroke [72]. 
Available data suggest that neither adjusted-dose unfrac-
tionated heparin nor fixed-dose low-molecular weight 
heparin (LMWH) provide adequate protection in pregnant 
patients with mechanical heart valves [68].  
Bioprosthetic Heart Valves  
  In patients with bioprosthetic valves without AF, long-
term therapy with aspirin (75-100 mg/d) is recommended [1, 
68]. For patients with bioprosthetic valves in the mitral 
position OAC with a target INR from 2.0 to 3.0 is recom-
mended during the first 3 months after valve insertion [68]. 
On the other hand, patients with bioprosthetic valves in the 
aortic position can be given either OAC (INR 2.0-3.0) or 
aspirin (80-100 mg/d) during the first 3 months after valve 
insertion [68]. Treatment with OAC has to be longer, from 3 
to 12 months, in patients with a history of systemic embo-
lism [68].  
Infective Endocarditis  
  Ischemic stroke is the most common neurological com-
plication of infective endocarditis occurring in approxi-
mately 20% of patients. Cerebral emboli are considerably 
more common in mitral valve endocarditis than in infection 
of the aortic valve. There is no convincing evidence that 
prophylactic anticoagulant therapy reduces the incidence of 
emboli in native valve endocarditis, and it is generally 
believed that the routine use of anticoagulants is not justified 
[68]. However, in patients with special indica-tions, such as 
AF, appropriate anticoagulant therapy should not be 
withheld [2]. Patients with prosthetic valves are at constant 
risk of thromboembolism and there are important reasons not 
to interrupt anticoagulant therapy in this circumstance. 
Embolic events in prosthetic valve endocarditis may repre-
sent dislodged vegetations or true thromboembolism unre-
lated to valve infection. While the incidence of the latter can 
be reduced by anticoagulation therapy, there is no evidence 
that embolic vegetations are controlled with this therapy. In 
previously undiagnosed patients who present with stroke, 
and who prove to have cardiac vegetations, it is often 
challenging to differentiate between infective endocarditis 
and nonbacterial thrombotic endocarditis (NBTE) [2]. Diag-
nostic clues such as fever or Roth’s spots (which suggest 
infective endocarditis) and metastatic tumors (which suggest 
NBTE) may be absent, and blood cultures may remain 
negative. Diffusion-weighted imaging (DWI) can provide 
additional diagnostic clues for patients with NBTE uniformly 
have multiple, widely distributed, small and large strokes, 
whereas patients with IE exhibit a host of different stroke 
patterns [73].  
Nonbacterial Thrombotic Endocarditis  
  Nonbacterial thrombotic endocarditis (NBTE) is reported 
most commonly in patients with adenocarcinoma, especially 
mucin-producing carcinomas of the lung or gastrointestinal 
tract, and lymphoma. The malignancy is usually widespread 
and cerebral infarction is a late complication, but in rare 
instances NBTE with cerebral infarction is the presenting 
sign of cancer. The reported incidence of systemic embolism 
in NBTE varies widely (14- 91%, average 42%) [74]. NBTE 
is more common in the aortic and mitral valves, but any 
valve may be affected. The pathogenesis of NBTE is not 
fully understood, but the most important predisposing factors 
appear to be an underlying coagulopathy, edema, degene-
ration of valvular collagen, and the effects of mucin-produ-
cing carcinomas. Treatment of NBTE is directed toward 
control of the underlying disease, in most instances neoplasia 
and/or sepsis, and toward treatment of thromboembolism. 
The most effective agent is heparin, and little benefit has 
been observed with vitamin K antagonists. Patients with 
NBTE and systemic or pulmonary emboli should be treated 
with full-dose unfractionated heparin IV or subcutaneous 
heparin [68]. Patients with disseminated cancer or debili-
tating disease with aseptic vegetations should also be treated 
with full-dose unfractionated heparin. The therapy of NBTE 
and cerebral intravascular coagulation is based on attempts 
to treat the underlying cancer and the activated coagulation. 
Heparin is more effective than OAC in treating the 
coagulopathy that accompanies cancer and a recent report 
confirms that low molecular weight heparin is more effective 
than OAC in preventing recurrent deep venous thrombosis 
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Libman-Sacks Endocarditis 
  Valvular involvement is the most frequent form of heart 
disease in systemic lupus erythematosus (SLE). Involvement 
includes valve masses also known as Libman-Sacks vegeta-
tions, valve thickening, valve regurgitation, and valve steno-
sis. On transesophageal echocardiography, the prevalence of 
valvular disease in SLE has been shown to be up to 60–74%. 
The incidence of ischemic cerebrovascular stroke in patients 
with SLE is 10–20%; in these patients, the existence of 
valvular involvement and left heart thrombi was proven in 
70–90% of cases [76]. A frequent concomitant appearance of 
valvulopathy, thromboembolic events (mostly stroke or TIA) 
and antiphospholipid antibodies has been observed. Ischemic 
manifestations, previously thought to be due to vasculitis, are 
usually due to thrombotic or cardioembolic events. Because 
of the increased incidence of stroke in SLE and the frequent 
valvulopathy in these patients, prophylactic antiplatelet 
therapy may be contemplated in all SLE patients. Anticoa-
gulant treatment should be considered independently of 
echocardiographic results in patients who had cerebrovas-
cular or systemic embolic events with no features of 
systemic SLE vasculitis [77].  
Mitral Annular Calcification and Aortic Valve Sclerosis 
  Mitral annular calcification (MAC) is characterized by 
calcium and lipid deposition in the annular fibrosa of the 
mitral valve, whereas aortic valve (AV) sclerosis results 
from similar accumulation involving the AV leaflets. MAC 
and AV sclerosis are associated with atherosclerosis risk 
factors that can promote left ventricular hypertrophy and left 
atrial enlargement, each of which has been reported to 
predict cerebrovascular events. The ACCP recommends 
long-term OAC in patients with MAC complicated by 
systemic embolism not documented to be calcific embolism 
[68]. For patients with repeated embolic events despite anti-
coagulation therapy, or in whom multiple calcific emboli are 
recognized, valve replacement should be considered.  
Mitral Valve Prolapse  
  The prevalence of mitral valve prolapse (MVP) in 
community-based studies is low (2.4%), and no more 
common among young patients with unexplained cerebral 
embolic events [78]. Nevertheless, it is recommended that 
patients with MVP and stroke receive antithrombotic therapy 
if alternative causes of brain ischemia cannot be identified 
[68]. Long-term aspirin (50-162 mg/d) is recommended for 
unexplained stroke in patients with MVP, while long-term 
OAC has only been suggested for MVP patients with 
recurrent vascular events despite aspirin [68].  
Bleeding Risk in Orally Anticoagulated Patients  
  The risk of major bleeding in patients receiving OAC is 
3% per year; and approximately 20% of major bleeding 
events are fatal [79]. Even at safe anticoagulant levels (INR 
2.0 to 3.0) annual rates of major, life threatening, and fatal 
bleeding are 2%, 1%, and 0.25%, respectively [80]. Every 
one-point rise in INR increases the risk of major bleeding by 
42% [81] and the interval 2.0-2.5 gives the lowest risk of 
stroke and death in patients with non valvular AF [82]. 
Concomitant hypertension, prior cerebrovascular accident, 
gastrointestinal bleeding or anticoagulation-related bleeding, 
use of aspirin or non steroidal anti-inflammatory drugs, older 
age, patient reliability, and the interactions of OAC with 
other medications contribute to the risk of bleeding [83].  
  The most frequent complication of OAC is gastro-
intestinal bleeding, but intracranial hemorrhage (ICH) is the 
main cause of fatal bleeding. In a pooled analysis of the first 
five trials with warfarin in patients with AF the annual rate 
of OAC-related ICH was 0.3% [7]. OAC-related ICH occurs 
at a rate of 2 to 9 per 100 000 population/year, an incidence 
which is 7 to 10 fold higher than in patients not receiving 
OAC [84]. The incidence of intracranial hemorrhage due to 
OAC is increasing, probably because of the larger number of 
elderly patients that receive this treatment, the association 
with aspirin, or the expanded use of OAC for stroke 
prevention [85].  
Long-term Secondary Stroke Prevention After OAC-
Related ICH 
  Another difficult decision in clinical practice is whether 
anticoagulants should be restarted and maintained 
indefinitely in patients with a history of OAC-related ICH 
and at risk of cardioembolic events. Stroke prevention in this 
situation needs to balance the risk/benefit of different 
antithrombotic options and the estimated risk of intracranial 
bleeding recurrence. To this aim, an important step is to 
establish the most likely cause of the bleeding. Whereas 
hypertensive vasculopathy appears to be the most important 
mechanism for ICH in deep hemispheric regions of the brain, 
cerebral amyloid angiopathy, may be the most common 
underlying pathophysiology for lobar ICH. The risk of 
recurrent hypertensive ICH can be decreased by an adequate 
control of hypertension [86], whereas cerebral amyloid 
angiopathy lacks any known treatment. In a prospective 
study of elderly patients who survived lobar ICH, recurrent 
ICH occurred in 22% at 2 years [87]. The rate of recurrent 
ICH in survivors of deep hemispheric ICH was estimated to 
be 2.1% per patient-year [88]. Therefore, in patients with 
lobar hemorrhage and major sources of embolism, decision 
analysis models based on retrospective data suggest that the 
strategy of “do not anticoagulate” appears robust [88]. 
Contrarily, the risks and benefits of anticoagulation are more 
closely balanced when applied to patients with deep hemis-
pheric ICH. In the latter case, OAC might be justified if the 
estimated risk of ischemic stroke is high. 
IMMEDIATE ANTIAGULATION AFTER ACUTE 
CARDIOEMBOLIC STROKE 
  Unfractionated heparin (UFH) is the most widely used 
anticoagulant in the acute stroke setting. Heparin binds to 
antithrombin through a unique glucosamine unit that is 
contained within a pentasaccharide sequence [89].Therefore, 
it has a potent anticoagulant effect mediated by this binding 
to antithrombin that converts it from a slow, progressive 
thrombin inhibitor to a very rapid inhibitor [90]. However, 
UFH also has important anti-inflammatory properties [91] 
that could be of relevance in the acute stroke setting, as 
inflammation, mainly when there is ischemia followed by 
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Thus, in a rat model of focal ischemia-reperfusion in the 
brain, an adjusted-dose of UFH was able to reduce the infarct 
volume by a 46% in comparison to rats treated with vehicle 
[93]. The reduction of infarct volume was partly mediated by 
anti-inflammatory mechanisms, as rats treated with UFH had 
higher plasmatic levels of interleukin-10, higher brain 
expression of hemeoxygenase-1, and lower endothelial 
induction of vascular cell adhesion mollecule-1 [93]. Also, in 
observational clinical studies, patients with acute stroke 
treated with UFH showed less prominent rise in serum acute 
phase reactants than patients treated with aspirin [94]. In 
another study patients treated with UFH had a lower increase 
in serum vascular cell adhesion molecule-1 in comparison to 
patients treated with aspirin [95]. These serologic findings of 
a reduced systemic inflammation in patients treated with 
UFH were associated with an improved clinical outcome 
after stroke [94, 95]. 
Clinical Evidence of Anticoagulation in Acute Ischemic 
Stroke 
  The value of anticoagulation in the acute stroke setting 
has been assessed in many different clinical trials. These 
studies have evaluated the efficacy of UFH, low-molecular-
weight heparins, or heparinoids. A meta-analysis of all the 
trials concluded that there is no role for immediate 
anticoagulation in acute ischemic stroke [96]. Patients with 
acute ischemic stroke receiving anticoagulants in the first 
two weeks of onset has 9 less ischemic recurrences per 1000 
patients [97]. However, this benefit is counterbalanced by a 
similar increase in symptomatic intracranial hemorrhages. 
Therefore, most clinical guidelines do not recommend 
anticoagulation in the acute phase of ischemic stroke [1]. 
The lack of evidence for heparin use in acute stroke has also 
been found in the subgroup analysis of patients with cardio-
embolic stroke secondary to AF [98]. 
  It has to be noted that the trials included in these analyses 
had many methodological problems [99]. For example, in the 
largest study [100] almost one third of patients had the first 
neuroimaging after the treatment was allocated, raising the 
possibility of the erroneous inclusion of approximately 500 
intracranial hemorrhages [99]. Moreover, UFH was not 
monitored in this trial and there was a great delay in the start 
of treatment. In many of these trials anticoagulation was no 
really immediate, therefore there is no adequate evidence of 
the utility of immediate anticoagulation in acute stroke [101]. 
Most of the studies with anticoagulation in the acute stroke 
setting allowed a 24 to 48 hours delay in the beginning of 
drug administration from symptom onset. This delay avoids 
an adequate neuronal protection, as the majority of events 
responsible of cell death take place in an earlier phase [99]. 
Thus, one observational study showed that in stroke patients 
with AF starting anticoagulation with UFH within the first 6 
hours of clinical onset was associated with a better clinical 
outcome, in comparison with patients in whom anticoagu-
lation was delayed [102].  
  The Rapid Anticoagulation Prevents Ischemic Damage 
(RAPID) trial was also a randomized trial evaluating 
immediate anticoagulation in ischemic stroke [103]. RAPID 
compared the effect of adjusted-dose UFH and aspirin 
administered in the first 12 hours of a non lacunar ischemic 
stroke. The mean treatment delay was 6.9 hours. In this trial 
it was shown that a higher risk of bleeding was associated to 
excessive anticoagulation [103]. Therefore, it is very relevant 
the fact that some trials of anticoagulation in the acute phase 
of stroke omitted anticoagulation monitoring. RAPID was an 
academic effort to reconcile science and simplicity, but 
unfortunately, a hopeless recruitment rate led to the prema-
ture termination of the study when only 67 patients had been 
included. Nevertheless, it was able to show a trend toward 
more effective prevention of stroke recurrence with UFH 
(0%) than aspirin (8.6%; P=0.09) and without an increment 
in serious bleeding (8.6% for aspirin, 6.3% for UH; P=0.71) 
[103]. 
  Later, in the pre-thrombolytic era, a randomized clinical 
trial compared the effects of UFH and placebo in the first 3 
hours after stroke onset [104]. The trial included 418 patients 
with an ischemic non lacunar stroke. In the group treated 
with UFH there was a better outcome at 3 months (self-
independent patients, 38.9% vs. 28.6%), fewer deaths 
(16.8% vs. 21.9%), and more symptomatic brain hemorr-
hages (6.2% vs. 1.4%), and more major extracerebral 
bleedings (2.9% vs. 1.4%) [104]. Therefore, this is the first 
randomized trial to show that UFH administered in the first 3 
hours after a non lacunar ischemic stroke is effective in 
reducing dependence when compared to placebo [104]. 
Although thrombolytic treatment with alteplase was known 
to be effective at that time, this treatment was not approved 
for clinical use in Europe yet. But it is important to keep in 
mind that the level of evidence for the efficacy of UFH in the 
acute stroke setting is reasonable. However, as the meta-
analysis will always include the larger trials with the above 
mentioned methodological problems, is highly improbable 
that UFH will have a role in the acute stroke treatment in the 
near future.  
When to Start Anticoagulation After a Cardioembolic 
Stroke for Secondary Prevention? 
  Delaying anticoagulation in stroke secondary to AF was 
advocated years ago to avoid early hemorrhagic transfor-
mation. However, from observational studies we know that 
carefully monitored UFH is safe, even in patients with large 
infarcts attributable to AF [105]. Thus, hemorrhagic conver-
sion and symptomatic hemorrhage in embolic stroke patients 
treated with UFH were not related to admission clinical 
severity or infarct size. The only parameter that was 
independently associated to hemorrhagic complications was 
an excessive prolongation of the activated partial thrombo-
plastin time [105].  
  The urgency of full anticoagulation is mainly justified in 
light of the molecular mechanisms of brain ischemia [106]. 
The delay of treatment for 24-48 hours is not very important 
if our primary aim is to decrease the risk of early stroke 
recurrence. However, treatment delay may be of vital rele-
vance if we aim primarily to improve functional outcome 
and reduce mortality.  
  Stroke secondary to AF has raised special interest 
because of higher risk of early stroke recurrence, although 
more recent information opposes this concept [101]. There-
fore, anticoagulation for early stroke prevention can be 
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the central issue for immediate anticoagulation in stroke 
could be defined as the tissue factor (TF) link [101]. TF is 
the primary cellular initiator of the coagulation cascade in 
vivo, and behaves as a hemostatic envelope diffusely expres-
sed in the adventitia of cerebral vessels. TF expression is 
also prominent in the human cortex [107]. Accordingly, any 
acute embolic stroke is a TF-mediated prothrombotic state 
that could theoretically be opposed with adequate anticoa-
gulation [101]. As UFH achieves faster anticoagulation 
levels than any other anticoagulant regimen, this therapy has 
been recommended for acute stroke patients if there are not 
contraindications [101]. For the efficacy of this treatment it 
is necessary to calibrate the activated partial thromboplastin 
time ratios to their corresponding heparin levels (0.3 to 0.5 
U/mL), careful monitoring, and frequent dose adjustments 
[103].  
Risk/Benefits of Early Anticoagulation in Patients with 
OAC-Related ICH 
  A therapeutic dilemma arises when a patient who 
requires full-dose anticoagulation for high risk of thrombo-
embolism is admitted with OAC-related ICH. Bertram and 
col. retrospectively studied 15 patients with serious cardiac 
conditions and ICH which occurred under anticoagulation 
[108]. In all instances, INR normalization was attempted as 
early as possible and received full-dose intravenous or low-
dose subcutaneous heparin. All patients that achieved a 1.5- 
to 2-fold elevation in partial thromboplastin time after 
normalization of the INR were discharged without compli-
cation. Alternatively, patients with only incomplete correc-
tion of the INR experienced relevant rebleeding within 3 
days, and 3 of 7 of the patients with normalized INR and 
without significant PTT elevation developed severe cerebral 
embolism. Rebleeding or expansion of the hemorrhage was 
associated with an INR > 1.5 after previous INR normali-
zation[108]. Small retrospective studies also showed with 
few exceptions [109] that none of the patients experienced 
rebleeding or embolic events after initiation of full dose 
heparin within 36 to 72 hours of OAC-ICH onset [110]. In 
one study early resumption of anticoagulation did not cause 
intracranial rebleeding even in patients that undergo early 
surgery of the hematoma [111]. 
  A retrospective series of 141 patients at the Mayo Clinic 
showed that the risk of having an ischemic stroke after 
discontinuation of OAC within 30 days of the ICH was less 
than 5%, although the mortality was 48% [112]. All embolic 
events occurred within the first 5 days after warfarin 
discontinuation. Of the 34 patients in whom anticoagulation 
therapy was restarted by day 14, none had recurrence of ICH 
during hospitalization. Tinker and Tarhan also observed in 
159 patients with mechanical heart valves undergoing 
elective surgery that none of the patients had in-hospital 
thromboembolic complications after discontinuing warfarin 
therapy [113]. Based on this small data base, the early 
initiation of full-dose anticoagulation in patients with OAC-
ICH cannot be recommended (or opposed). While early 
initiation of full-dose anticoagulation was not followed in 
these studies by a clear reduction of the risk of embolism, the 
low statistical power of the studies cannot rule out significant 
differences. Moreover, few patients had the biological effects 
of heparin adequately monitored in these studies, which is a 
crucial step for heparin safety [108]. Avoiding heparin for 1 
to 2 weeks after the OAC-related ICH yields a complete 
reduction of rebleeding, but the incidence of thrombin-
mediated hematoma growth or edema formation it is not 
known.  
  Weight-adjusted heparin has been used safely in other 
bleeding conditions of the central nervous system, including 
hemorrhagic stroke [105, 114] or cerebral venous infarctions 
[115]. In these diseases, the bleeding respond to mechanisms 
different from OAC-related ICH but serve to illustrate that 
heparin does not prevent full recovery of certain brain 
hematomas. Lacking randomized clinical trials to establish 
the value of full anticoagulation in patients with OAC-ICH, 
therapeutic decisions should be consider case by case. Yet, 
clinicians should be aware that full anticoagulation must not 
be started before stable blockade of OAC effects. The greater 
safety of weight-adjusted anticoagulant nomograms, and the 
importance of strict monitoring of the biological effects of 
heparin have also to be considered [106].  
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